期刊
IMMUNOLOGY LETTERS
卷 262, 期 -, 页码 27-35出版社
ELSEVIER
DOI: 10.1016/j.imlet.2023.08.005
关键词
microRNA; Cell therapy; T cell; miR-17-92; Synthetic biology; Non-coding RNA
类别
Cellular therapy has evolved from traditional blood transfusion to complex manufacturing of CAR-T cells. Basic knowledge of cell biology and molecular genetics can improve modern cellular therapy products. Although most cell engineering efforts focus on proteins, miRNAs also play an important role in posttranscriptional gene regulation.
Owing to Karl Landsteiner's discovery of blood groups, blood transfusions became safe cellular therapies in the early 1900s. Since then, cellular therapy made great advances from transfusions with unmodified cells to today's commercially available chimeric antigen receptor (CAR) T cells requiring complex manufacturing. Modern cellular therapy products can be improved using basic knowledge of cell biology and molecular genetics. Emerging genome engineering tools are becoming ever more versatile and precise and thus catalyze rapid progress towards programmable therapeutic cells that compute input and respond with defined output. Despite a large body of literature describing important functions of non-coding RNAs including microRNAs (miRNAs), the vast majority of cell engineering efforts focuses on proteins. However, miRNAs form an important layer of posttranscriptional regulation of gene expression. Here, we highlight examples of how miRNAs can successfully be incorporated into engineered cellular therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据